SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Bill Wexler's Profits of DOOM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bill Wexler who wrote (565)4/8/1998 11:11:00 PM
From: Biojunkie  Read Replies (3) of 4634
 
Bill, Bill, Bill,
Have you read any of the company's literature. It appears that a unique formulation of DHEA (not avaliable at your corner health food store) was researched and discovered to have a new mechanism of action in preventing HIV from replicating in it's host cell. In the company's literature it appears that this new way of stoping the virus from replicating involves naturally interupting the cells energy source needed by the virus to replicate. It appears that key hormones in the body or anologs of those hormones may inhibit cellular factors required by the virus to replicate. The technology appears to start with DHEA as a basis for studying this mechanism and finding more potent anologs that can be made to be more bioavailable and thereby effective. It screams MONOTHERAPY potential HOMERUN.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News